Clinical Trials Logo

Filter by:
NCT ID: NCT04000347 Withdrawn - Foot Dermatoses Clinical Trials

A Study of Efficacy of Benzoyl Peroxide Regimens in Treatment of Unpleasant Foot Odor

Start date: June 26, 2019
Phase: Phase 4
Study type: Interventional

This study aimed to study the efficacy of topical 2.5% benzoyl peroxide, compared to 5% benzoyl peroxide in treatment of unpleasant foot odor, which was considered as major problem related to pitted keratolysis.

NCT ID: NCT03801889 Withdrawn - Iron Overload Clinical Trials

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Start date: August 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and tolerability of SP-420 and it's efficacy in terms of lowering iron in subjects with Beta-thalassemia or other rare anemias who need regular blood transfusions.

NCT ID: NCT02624999 Withdrawn - Clinical trials for Squamous Cell Carcinoma Head and Neck

Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck

Start date: December 2016
Phase: Phase 2
Study type: Interventional

Phase II, Randomized, Non-Inferiority Study Comparing an Individualized Cancer Vaccine (AlloVax™) to Chemotherapy in Subjects with R/M SCCHN .

NCT ID: NCT01906112 Withdrawn - Clinical trials for Carcinoma Breast Stage IV

Role of Surgery for the Primary in Patients With Breast Cancer Stage IV.

Start date: August 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine benefits of surgery for the primary in patients with breast cancer stage IV in randomized controlled study.

NCT ID: NCT01741038 Withdrawn - Clinical trials for Metastatic Colorectal Cancer

AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer

Start date: December 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This is a personalized anti-cancer vaccine protocol which includes an in-situ (in the body) cancer vaccine step which combines killing a single metastatic tumor lesion by use of cryoablation in order to cause the release of tumor-specific markers to the immune system and then injecting bioengineered allogeneic immune cells (AlloStim) into the lesion as an adjuvant in order to modulate the immune response and educate the immune system to kill other tumor cells where ever they reside in the body.

NCT ID: NCT01600963 Withdrawn - Clinical trials for Multi-drug Resistant Tuberculosis

A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis

Start date: March 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide safety and efficacy data for TMC207 and to demonstrate that TMC207 added to a background regimen (BR) is superior to treatment with the BR plus placebo.

NCT ID: NCT01546935 Withdrawn - Influenza Clinical Trials

Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under One

Start date: December 2012
Phase: Phase 2/Phase 3
Study type: Interventional

Currently, there is no treatment for children less than one year of age with influenza related lower respiratory tract infection that is either considered standard or registered in any country. This dismal scenario exists even though influenza related LRTI is a significant illness causing morbidity and mortality, especially in children less than 6 months of age. Avian influenza has been reported rarely in children less than one. There are no data in Vietnam and very few data in Thailand on the burden of influenza in children less than one. This young age group suffers high mortality. Oseltamivir may be beneficial in such children. This is basis of this trial.

NCT ID: NCT01507935 Withdrawn - Healthy Infants Clinical Trials

Colonisation Resistance Study

ColoR
Start date: January 2012
Phase: Phase 2
Study type: Interventional

This study is initiated to investigate the effect of infant formulas with added specific prebiotic oligosaccharides on the reduction of specific potential pathogens and/or toxins.

NCT ID: NCT01442428 Withdrawn - Tuberculosis Clinical Trials

Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial

Start date: January 2014
Phase: Phase 2/Phase 3
Study type: Interventional

Tuberculosis is the most common opportunistic infection (OI) in HIV-infected persons worldwide, including in South East Asia. Significant numbers of patients experience tuberculosis-related paradoxical immune reconstitution inflammatory syndrome (TB-IRIS) after ART initiation, yet the optimal treatment of TB-IRIS is unknown. A recent randomized-controlled trial showed the benefit of prednisone over placebo in reduction of days of hospitalization and invasive procedures. The investigators hypothesize that nonsteroidal anti-inflammatory drugs (NSAIDs) are as effective as corticosteroids for treatment of non-life threatening TB-IRIS in HIV-infected patients and hypothesize that adjunctive treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (Statins) may improve the outcomes. This is a randomized controlled trial with a 2x2 factorial design to test the relative benefit of corticosteroids, NSAIDS, and Statins for the symptomatic and immunologic control of TB-IRIS.

NCT ID: NCT01389986 Withdrawn - Paralytic Ileus Clinical Trials

Effects of Gum Chewing on Recovery of Bowel Function Following Abdominal Surgery for Endometrial and Ovarian Cancer

Start date: July 2011
Phase: Phase 2/Phase 3
Study type: Interventional

Following extensive abdominal surgery for the treatment of endometrial or ovarian cancer, paralytic ileus frequently develops. Gum chewing can promotes the return of bowel function through the cephalic-vagal reflex and increased intestinal enzymes secretion. The objectives of this study are to evaluate effects of adding gum chewing to the conventional postoperative feeding protocol on the return of bowel function, its related complications, and patients' satisfaction.